DDInter246 DDInter782
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol].
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Budesonide {u} (Compound) resembles {v} (Compound) Flurandrenolide
Budesonide {u} (Compound) treats {v} (Disease) asthma
Budesonide {u} (Compound) binds {v} (Gene) CYP3A4
Budesonide {u} (Compound) upregulates {v} (Gene) P4HA2
Budesonide {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Budesonide {u} (Compound) downregulates {v} (Gene) RAP1GAP
Budesonide {u} (Compound) causes {v} (Side Effect) Pain
Budesonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoprenaline
Budesonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Budesonide (Compound) resembles Flurandrenolide (Compound)
Budesonide (Compound) treats asthma (Disease)
Budesonide (Compound) binds CYP3A4 (Gene)
Budesonide (Compound) upregulates P4HA2 (Gene)
Budesonide (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Budesonide (Compound) downregulates RAP1GAP (Gene)
Budesonide (Compound) causes Pain (Side Effect)
Budesonide may cause a minor interaction that can limit clinical effects when taken with Isoprenaline
Budesonide may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab